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We report the successful encapsulation and elution of recombinant murine IL-12 (rmIL-12) from poly(lactide-co-glycolic) acid
(PLGA) nanospheres (IL-12-NS) synthesized using the double emulsion/solvent evaporation (DESE) technique with
microsphere depletion through ultracentrifugation. Images obtained with scanning electron microscopy (SEM) showcased a
characteristic spherical shape with a mean particle diameter of 138:1 ± 10:8 nm and zeta potential of −15:1 ± 1:249 mV. These
values suggest minimal ﬂocculation when in solution, which was reﬂected in an in vivo biodistribution study that reported no
observed morbidity/mortality. Encapsulation eﬃciency (EE) was determined to be 0:101 ± 0:009% with average particle
concentration obtained per batch of 1:66 × 109 ± 4:45 × 108 particles/mL. Disparate zeta (ζ) potentials obtained from both
protein-loaded and protein-unloaded batches suggested surface adsorption of protein, and confocal microscopy of BSA-FITCloaded nanospheres conﬁrmed the presence of protein within the polymeric shell. Furthermore, elution of rmIL-12 from IL12-NS at a concentration of 500 million particles/mL was characterized using enzyme-linked immunosorbent assay (ELISA).
When IL-12-NS was administered in vivo to female BALB/c mice through retroorbital injection, IL-12-NS produced a
favorable systemic cytokine proﬁle for tumoricidal activity within the peripheral blood. Whereas IFN-γ nadir occurred at 72
hours, levels recovered quickly and displayed positive correlations postburst out to 25 days postinjection. IL-12-NS
administration induced proinﬂammatory changes while prompting minimal counterregulatory increases in anti-inﬂammatory
IL-10 and IL-4 cytokine levels. Further, while IL-6 levels increased to 30 folds of the baseline during the burst phase, they
normalized by 72 hours and trended negatively throughout the sill phase. Similar trends were observed with IL-1β and CXCL1, suggesting a decreased likelihood of progression to a systemic inﬂammatory response syndrome-like state. As IL-12-NS
delivers logarithmically lower amounts of IL-12 than previously administered during human clinical trials, our data reﬂect the
importance of IL-12-NS which safely create a systemic immunostimulatory environment.

1. Introduction
Immunostimulation is a rapidly evolving concept in the ﬁeld
of immunooncology. While once a controversial topic, it is
now well-established that intact immune systems can kill
tumor cells [1]. The indiscriminate cytotoxicity of innate
immunity combined with the antigen-speciﬁc cell surface
receptor repertoire of adaptive immunity forms a highly
eﬀective network of host defense mechanisms that manage

bodily insults of various etiologies, including tumorigenic
cell transformation [2–4]. Currently, the most successful
application of tumor immunotherapy has occurred using
anticytotoxic T-lymphocyte-associated protein 4- (CTLA4-) and/or antiprogrammed death-ligand 1- (PD-L1-)
directed monoclonal antibodies as adjuvant treatment for
lung and skin cancers [5]. However, checkpoint blockade
alone has repeatedly failed to improve survival in other cancers including metastatic sarcoma over the current standard
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of care [6], likely due to a combination of tumor-induced
immunosuppressive forces that circumnavigate checkpoint
blockade alongside extensive tumor cell pleomorphism [7].
Our group has shown that treatment modalities employing
these “blocking the block” strategies can fail by prompting
the emergence of tumor escape mechanisms [8].
Preclinical studies have shown that interleukin- (IL-) 12,
an immunostimulatory cytokine, can induce strong antitumor responses against various malignancies. Compared to
the monoclonal antibody checkpoint blockade, IL-12 is
active over a broader spectrum of immune functions;
examples of the eﬀects of IL-12 include diﬀerentiation of T
helper cells into the type one (TH1) phenotype, stimulation
of interferon-gamma production by macrophages, and
enhanced cytotoxicity of natural killer (NK) cells [9, 10].
Preclinical studies have also shown that the antitumor eﬀects
of IL-12 are most pronounced when given systemically [11].
Unfortunately, clinical use of recombinant IL-12 systemically has been complicated by inadvertent overstimulation
in the form of systemic inﬂammatory response syndrome
(SIRS) and T cell exhaustion (TCE) [12], as high loading
doses of free protein were needed to ensure adequate distribution to target tissues. Nevertheless, while the side-eﬀect
proﬁles of systemic high-dose IL-12 administration are
toxic, low doses of IL-12 are generally safe [13]. If formulated correctly, recombinant IL-12 may be used to alter the
local cytokine environment and encourage antitumor
immunity at a point far enough upstream in the inﬂammatory cascade to induce a multimodal downstream response,
ultimately leading to a decreased likelihood of treatment
resistance. Therefore, low-dose immunostimulatory cytokines coupled with proper real-time patient monitoring to
ensure immune safety may produce subtle yet clinically beneﬁcial antitumor immune activity without unwanted overstimulation [14].
Poly(lactide-co-glycolic) acid (PLGA) drug delivery vectors are Food and Drug Administration (FDA) approved
and can elute a wide variety of substances as the polymer
coating breaks down into metabolic intermediates [15].
Drug solubility, bioavailability, and particle stability can be
individually altered by the organic coating, allowing for large
shifts in the pharmacokinetic and pharmacodynamic properties of the encapsulate [16]. The negatively charged surfaces of PLGA particles are repelled by the glycocalyx
which, along with their smaller size, allows for increased
deposition within the interstitial space where they can elute
their contents undisturbed [17]. Furthermore, to be used in
systemic settings (versus intratumoral injections), nanospheres must be able to achieve safe and eﬀective travel
through the microvasculature of an organism (with capillaries being approximately 4-9 μm in diameter) with minimal risk of forming emboli [18]. Encapsulating IL-12
within PLGA nanospheres is a potential strategy to achieve
adequate biodistribution and tissue deposition of sensitive
protein molecules without the need for toxic loading doses
that resulted in the failure of clinical trials in the past [13].
While there have been several studies describing the
synthesis of IL-12-loaded microspheres [19–35], to date,
successful submicron encapsulation and elution of a struc-
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turally intact protein have not been well established. In this
manuscript, we describe the synthesis and characterization
of IL-12-loaded nanospheres (IL-12-NS), as well as the
in vivo cytokinome proﬁle produced when administered
systemically.

2. Materials and Methods
2.1. Materials. Dichloromethane (DCM, #320269), Resomer
RG 756 S (PLGA, #719927), NaCl (#7647-14-5), and poly(vinyl alcohol) (PVA, #341584) were purchased from
Sigma-Aldrich (St. Louis, MO). Albumin from bovine serum
(BSA), FITC conjugate (BSA-FITC, #A23015), penicillinstreptomycin 10,000 U/mL (Pen-Strep, #15140122), and
Alexa Fluor 647 carboxylic acid, tris(triethylammonium) salt
(Alexa 647, #A33084) were purchased from Thermo Fisher
Scientiﬁc (Waltham, MA). Recombinant mouse IL-12
(p70) (carrier free) (rmIL-12, #577008) and mouse IL-12
(p70) ELISA MAX deluxe ELISA kits (#433606) were purchased from BioLegend (San Diego, CA). Gibco Fetal Bovine
Serum Qualiﬁed Heat Inactivated US Origin (HI-FBS,
#MT35011CV) and Corning Cell Culture Buﬀers: Dulbecco’s
Phosphate-Buﬀered Salt Solution 1X (DPBS, #21031CV) were
purchased from Fisher Scientiﬁc (Pittsburgh, PA). Female
BALB/c mice (6-8 weeks of age) (#000651) were purchased
from the Jackson Laboratory (Bar Harbor, ME).
2.2. Synthesis of Blank and Alexa 647-, BSA-FITC-, and
rmIL-12-Loaded PLGA Nanospheres Using the Double
Emulsion/Solvent Evaporation (DESE) Method with
Microsphere Removal and Ultracentrifugation. To create
the oil phase, 800 mg of Resomer RG 756 S PLGA was dissolved in 32 mL DCM at room temperature (RT) for two
hours using a magnetic stir bar at 500 RPM. To create the
aqueous phase (2% PVA) of the emulsion, 2400 mg PVA
and 96 mg NaCl were dissolved in 120 mL deionized water
and microwaved for 10-second bursts in a standard kitchen
microwave on the high setting until clear, then cooled on ice.
Next, the ﬁrst emulsion was made by suspending the encapsulation substrate (Alexa 647 [5 mg], BSA-FITC [5 mg], or
rmIL-12 [25 μg]) in 1200 μL DPBS and adding to the oil
phase, which was promptly stirred at 17500 RPM for 6
minutes on ice using a tissue homogenizer. Blank particles
were prepared similarly, however, with no encapsulate.
The second emulsion was formed by slowly pouring the
ﬁrst emulsion into 120 mL of the 2% PVA salt solution
while being emulsiﬁed with the tissue homogenizer at
17500 RPM and continuing for a total of 8 minutes. The
resulting suspension was then stirred for 16 hours with a
magnetic stir bar at 750 RPM to evaporate the organic solvent. Once the solvent was evaporated, the resulting solution was spun at 3500 RPM thrice; following each spin,
supernatant was collected and placed on ice, with the
resulting pellet being resuspended. The particles were then
washed twice with deionized water via ultracentrifugation
at 20000 RPM for 40 minutes at 4 degrees Celsius before
ﬂash-freezing in liquid nitrogen and storing short term
at -20 degrees Celsius.
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2.3. Nanosphere Morphology. The morphology of the nanospheres was determined via scanning electron microscopy
(SEM) using a Hitachi S-4700 scanning electron microscope
(Tarrytown, NY). Brieﬂy, lyophilized samples were mounted
on metal stubs with carbon tape and prepared for imaging
with a gold-targeting Denton Desk V sputter and carbon
coater (Moorestown, NJ), which applies a thin layer of gold
to the biosample under an argon gas atmosphere. To test the
stabilizing ability of the sugar additive trehalose during the
lyophilization process, 1 mL of 50 mmol/mL trehalose was
added to a 1 mL aliquot of blank nanoparticles suspended
in deionized water for a ﬁnal trehalose concentration of
25 mmol/mL prior to lyophilization and subsequent gold
sputter/SEM imaging.
2.4. Nanosphere Characterization. Nanosphere count and
size distribution were determined in duplicate using the
Malvern Panalytical NanoSight NS300 (Malvern, UK) at
RT in deionized water with dilution factors of 1 : 50 and
1 : 14 for unloaded and rmIL-12-loaded batches, respectively.
Nanosphere zeta potentials were determined using the Malvern Panalytical Zetasizer Nano Z at RT in deionized water
with dilution factor of 1 : 50 for both unloaded and loaded
batches. Results included are the product of biological duplicates (n = 2).
2.5. Nanosphere BSA-FITC Encapsulation. Z-stack images of
BSA-FITC-loaded PLGA nanospheres were created using
the Zeiss 710 confocal microscope (Cambridge, UK).
2.6. Nanosphere rmIL-12 Elution Proﬁle. 500 million particles/mL of IL-12-NS were prepared in a nanosphere release
buﬀer (NRB, 10% HI-FBS and 100 units/mL Pen-Strep in
DPBS). At speciﬁed time points, nanospheres were pelleted
at 10000 × g for 15 minutes, and an aliquot of supernatant
was sampled. In between sampling times, suspensions were
incubated at 37 degrees Celsius with continuous agitation
(750 RPM) using a Benchmark Scientiﬁc MultiTherm
Cool-Heat-Shake (Edison, NJ). Each aliquot was stored at
4 degrees Celsius for at least 24 hours to equilibrate with
the release buﬀer before determining rmIL-12 concentration
through ELISA. Results included are the product of biological duplicates (n = 2).
2.7. Estimation of Encapsulation Eﬃciency (EE). The amount
of IL-12 encapsulated and released by the IL-12-NS was estimated by summing the protein concentrations measured by
ELISA over time. This sum was multiplied by the particle
concentration (PC) as determined by NanoSight and the
total volume of synthesized particles (V); this value was then
divided by the total mass of IL-12 added during synthesis
(25 μg) as shown in the following equation:

EE =


∑i=5
pgIL‐12
i ∗ PC ∗ V
i=0
25 μg

:

ð1Þ

Results included are the product of n = 2 biological
duplicates.

2.8. In Vivo Alexa 647-Loaded PLGA Nanosphere Substrate
Biodistribution and Safety Study. Female BALB/c mice
received 1 mg/kg intravenous (tail vein) or intraperitoneal
(i.p.) injections of Alexa 647-loaded PLGA nanospheres suspended in sterile saline. The In Vivo Imaging System (IVIS®
SpectrumCT In Vivo Imaging System, PerkinElmer, Waltham, MA) was used to monitor ﬂuorescence intensity and
biodistribution over a 30-minute interval, at which time animals were humanely euthanized by CO2 asphyxiation and
their femurs and lungs harvested for Z-stack confocal
microscopy (Zeiss Violet Confocal, Jena, Germany).
2.9. In Vivo Administration of IL-12-Loaded PLGA
Nanospheres and Cytokine Analysis. Thirty female BALB/c
mice received retroorbital (r.o.) administration of 250 million IL-12-loaded nanospheres in 250 μL sterile saline.
Groups of 3 mice were euthanized at the following time
points: 5 minutes, 6 hours, 12 hours, 24 hours, 48 hours,
72 hours, 96 hours, 11 days, 18 days, and 25 days (n = 3).
At each time point, blood was collected through cardiac
puncture. Blood concentrations of interferon-gamma (IFNγ), IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, chemokine
(C-X-C motif) ligand 1 (CXCL-1), and tumor necrosis
factor-alpha (TNF-α) were analyzed using the Meso Scale
Discovery (Rockville, MD) V-PLEX Proinﬂammatory Panel
1 Mouse Kit per manufacturer protocol. Treated animals
were compared to pooled control animal samples using Student’s t test with α = 0:05.

3. Results
3.1. Nanosphere Synthesis, Morphology, and Characterization.
Unloaded (blank), Alexa 647-, BSA-FITC-, and rmIL-12loaded PLGA nanospheres (IL-12-NS) were successfully synthesized using the DESE method with ultracentrifugation as
described. The morphology of both blank (Figures 1(a)–1(c))
and rmIL-12-loaded (Figures 2(b) and 2(c)) PLGA nanospheres was determined using scanning electron microscopy (SEM) to be spherical in shape with a mean particle
diameter of 201:7 ± 6:7 nm and 138:1 ± 10:8 nm, respectively; the blank and rmIL-12-loaded PLGA nanosphere
counts for each batch were determined to be 6:49 × 109 ±
6:19 × 108 particles/mL and 1:66 × 109 ± 4:45 × 108 particles/mL, respectively (Table 1). The introduction of 25 g
rmIL-12 during particle synthesis resulted in a decrease in
zeta potential magnitude from −21:3 ± 0:808 mV to −15:1 ±
1:249 mV (Table 1).
3.2. Nanosphere BSA-FITC Encapsulation and Z-Stack
Imaging. To determine whether the synthesized nanospheres
could indeed encapsulate protein and not merely adsorb it to
the outer surface, 5 mg FITC-labeled BSA was loaded into
the nanospheres; the resulting batch was imaged using confocal microscopy to visualize the internal structure. As
shown in Figure 2(a), Z-stacking analysis conﬁrmed that
BSA was both adsorbed to the surface and incorporated
within the polymeric shell.
3.3. IL-12-NS Elution Proﬁle. 500 million particles/mL of IL12-NS were eluted in NRB; aliquots taken daily were
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WVUSRF 5.0 kV 12.0 mm ×2.50 k SE (M.-150) 1/11/2019

WVUSRF 5.0 kV 12.3 mm ×9.00 k SE (M.-150) 1/11/2019

20.0 um

(a)

5.00 um

(b)

WVUSRF 5.0 kV 12.0 mm ×5.00 k SE (M) 1/14/2019

10.0 um

(c)

Figure 1: Scanning electron microscopy (SEM) images of unloaded (blank) poly(lactide-co-glycolic) acid (PLGA) nanospheres lyophilized
without (a, b) and with (c) 25 mM trehalose at 2500x, 9000x, and 5000x magniﬁcations, respectively.

subsequently analyzed with ELISA for heterodimeric p70
rmIL-12 concentrations released over time. The elution
proﬁles for each particle concentration are shown in
Figure 3, which displayed “burst” (days 0-1) and “sill”
(days 1-5) phases characteristic of PLGA particle nanoencapsulation [36].
3.4. Estimation of Encapsulation Eﬃciency (EE). The amount
of encapsulated rmIL-12 available for elution was estimated
using Equation (1), and EE was determined to be 0:101 ±
0:009% (Table 1).
3.5. In Vivo Alexa 647-Loaded PLGA Nanosphere Substrate
Biodistribution and Safety. We sought next to investigate
whether the contents of PLGA nanospheres distribute systemically following injection without adverse events, including death. To accomplish this goal, PLGA nanospheres were
loaded with Alexa 647 and administered to female BALB/c
mice either intravenously (via tail vein) or intraperitoneally
(i.p.) and monitored through IVIS imaging. At 30 minutes
postinjection, both routes of administration resulted in systemic distribution of nanosphere contents (Figure 4(a))
without any signs of morbidity or mortality. Fluorescent
microscopy following necropsy showed distribution of the
encapsulate to both the lung and bone (Figure 4(b)).

3.6. In Vivo Characterization of Cytokinome Proﬁle Induced
by the Administration of IL-12-NS. We next evaluated the
in vivo cytokinome proﬁle induced by intravenous injection
of 250 million IL-12-NS into BALB/c mice. This concentration was chosen because it was the highest particle count:
saline ratio the mice could tolerate retroorbitally (data not
shown). Following injection, groups of three [3] mice were
euthanized at a total of ten [10] time points over the course
of 25 days and blood cytokine concentrations were determined, normalized to control mice, and presented as the fold
change from physiological baseline. For reference, a fold
change of one (1) indicates equal cytokine levels in comparison to control, whereas a fold change of two (2) or one-half
(0.5) indicates a respective doubling or halving from physiological levels. Although an oversimpliﬁcation, for charting
purposes, the cytokines were split into three groups by their
generalized tumor-destroying (IFN-γ, IL-2, and IL-5),
tumor-promoting (IL-10 and IL-4), or SIRS-associated (IL1β, IL-6, CXCL-1, and TNF-α) properties [37–62].
3.6.1. Tumor-Destroying Cytokines: IFN-γ, IL-2, and IL-5.
During the burst phase, blood concentrations of IFN-γ were
signiﬁcantly increased at 6 hours (p < 0:05) but signiﬁcantly
decreased at 12 hours (p < 0:05) (Figure 5(a)). During the sill
phase, IFN-γ was also signiﬁcantly decreased at 48 and 72
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WVUSRF 5.0 kV 12.0 mm ×8.00 k SE (M) 1/14/2019

WVUSRF 5.0 kV 12.0 mm ×25.0 k SE (M) 1/14/2019

5.00 um

(a)

2.00 um

(b)
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Figure 2: (a, b) Scanning electron microscopy (SEM) images of lyophilized recombinant mouse IL-12- (rmIL-12-) loaded PLGA
nanospheres at 8000x and 25000x magniﬁcations, respectively. (c) Fluorescein isothiocyanate- (FITC-) conjugated bovine serum albumin
(BSA) was loaded into poly(lactide-co-glycolic) acid (PLGA) nanospheres, and the product was visualized for protein incorporation
through confocal microscopy.
Table 1
Average particle count
Average ζ
(particles/mL)
potential (mV)
Unloaded 6:49 × 109 ± 6:19 × 108
Loaded

9

8

1:66 × 10 ± 4:45 × 10

−21:3 ± 0:808

Average EE
(%)

Similar to IFN-γ, IL-5 also showed a positive trend across
the sill phase, exceeding physiological levels at both the 11and 18-day time points postinjection although it was not statistically signiﬁcant (Figure 5(b)).

N/A

−15:1 ± 1:249 0:101 ± 0:009

EE: encapsulation eﬃciency (%).

hours (p < 0:05); however, it showed a positive trend across
the sill phase (R = 0:77), with IFN-γ being elevated an average of 3.08-folds over the control at 25 days postinjection
(p = 0:052, Figure 5(b)).
IL-2, albeit below physiologic levels, showed no signiﬁcant
fold changes during the burst phase (Figure 5(a)) but was signiﬁcantly decreased at day 18 (p < 0:05) (Figure 5(b)). Further,
it showed a positive trend across the sill phase; however, it did
not return to baseline production levels during the 25-day
sampling period (R = 0:48, Figure 5(b)).
Much like IL-2, IL-5 showed no signiﬁcant fold changes
during the burst phase (Figure 5(a)) but was signiﬁcantly
decreased at 24 hours postinjection (p < 0:05) (Figure 5(b)).

3.6.2. Tumor-Promoting Cytokines: IL-10 and IL-4. Tumorpromoting cytokines IL-10 and IL-4, though elevated in
the 6-hour sample, showed no signiﬁcant changes during
the burst phase (Figure 5(c)). However, during the sill phase,
IL-10 and IL-4 concentrations trended downward and
remained near or below physiological levels after the 72and 48-hour time points, respectively (R = −0:51 and
−0.37, respectively, Figure 5(d)).
3.6.3. SIRS-Associated Cytokines: IL-1β, IL-6, CXCL-1, and
TNF-α. IL-1βwas signiﬁcantly increased at only the 6-hour
time point (p < 0:05) throughout the 25-day sampling period
postinjection during both the burst (Figure 5(e)) and sill
phases (Figure 5(f)). It also showed a negative correlation
across the sill phase, returning from those elevated levels to
at or below physiological levels (R = −0:54, Figure 5(f)).
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Figure 3: Cumulative amount of protein eluted over time from
recombinant mouse IL-12-loaded poly(lactide-co-glycolic) acid
(PLGA) nanospheres at a concentration of 500 million particles/
mL as measured by ELISA. Nanospheres were eluted in 500 μL of
release buﬀer (NRB; 10% heat-inactivated fetal bovine serum [HIFBS] and 100 units/mL Pen-Strep in DPBS) under constant
agitation. Samples were collected from the supernatant following
centrifugation of the pellet at 10000 × g for 15 minutes at 4
degrees Celsius.

IL-6 was signiﬁcantly elevated during the burst phase at
6- (p < 0:01) and 12- (p < 0:001) hour time points, reaching
a transient maximum of a 30.58-fold increase over the control
at 6 hours (Figure 5(e)). During the sill phase, IL-6 remained
signiﬁcantly increased at 24 hours (p < 0:05), 48 hours
(p < 0:01), 96 hours (p < 0:001), and 18 days (p < 0:05) but,
overall, trended downward (R = −0:60) and was statistically
equivalent to the control by 25 days (Figure 5(f)).
During the burst phase, CXCL-1 was signiﬁcantly elevated at 5 minutes (p < 0:05), 6 hours (p < 0:001), and 12
hours (p < 0:05). During the sill phase, it was signiﬁcantly
increased at 24 hours (p < 0:01) but displayed an overall negative correlation, returning to near baseline levels by the 72hour time point (R = −0:60, Figure 5(f)).
TNF-α was signiﬁcantly decreased during the burst
phase at 5 minutes (p < 0:05) and 12 hours (p < 0:001)
(Figure 5(e)). During the sill phase, TNF-α was signiﬁcantly
increased at 48 and 72 hours (p < 0:05) (Figure 5(f)). Interestingly, TNF-α was signiﬁcantly decreased at 25 days (p < 0:01)
(Figure 5(f)). Similar to the other SIRS-associated cytokines
mentioned previously, TNF-α showed a negative correlation
across the sill phase, returning to normal physiologic levels
(R = −0:46, Figure 5(f)).

4. Discussion
Multiple cytokines have been shown to exhibit potent antitumor properties in preclinical studies; examples include
IL-12, IL-2, IL-17, and IFN-γ among others [63]. IL-12, produced mainly by tumoricidal TH1 cells, showed promise in
animal models against a wide variety of tumor types including sarcoma, with best responses achieved through systemic
versus local (intratumoral) administration [11]. Unfortunately, recombinant IL-12 cytokine therapy thus far has produced underwhelming results in human patients. Clinical
trials conducted in the 1990s required high loading doses

of IL-12 to achieve adequate tissue biodistribution and
resulted in TCE, SIRS, and ultimately worse outcomes [13].
In contrast, low-dose IL-12 given over prolonged periods
has been shown to induce tumor regression without overstimulation, though there are currently few cases reported
in the literature using this treatment strategy [64, 65].
Encapsulation in PLGA nanospheres may provide an opportunity to achieve slow and controlled delivery of IL-12 in a
systemic fashion while ensuring delivery of contents to
peripheral tissues.
IL-12-NS eluted picogram-scale protein doses corresponding to the equivalent of approximately 2-3.3 ng over
the course of ﬁve days, and their diameter fell within a size
distribution range of 100-200 nm. Notably, the zeta potential
of loaded batches decreased in magnitude an average of
6.2 mV, which may reﬂect adsorption of rmIL-12 to the
outer shell of the polymer coating [66]. The EE of our synthesis method was low (0.101%) and likely was due to the incorporation of rmIL-12 within microspheres, which comprises
most of the formed product and is ultimately discarded during
nanosphere puriﬁcation. While other methods of synthesis
(e.g., sonication) could have been employed for better encapsulation, bioactive IL-12 has a dimeric structure and is held
together by a single disulﬁde bond that could easily be disrupted by vigorous agitation methods.
The in vivo studies provide a glimpse of the eﬀects of IL12-NS therapy on the systemic immune system. The biodistribution study suggested that the PLGA nanospheres (1)
did not immediately ﬂocculate and subsequently embolize
and (2) distributed their contents systemically. As our group
is primarily interested in metastatic osteosarcoma, we were
especially excited to witness the distribution of nanosphere
contents to the bone and lung. Further, V-PLEX analysis
revealed signiﬁcant changes in the cytokinome proﬁles of
IL-12-NS-treated mice. Corresponding to the leukopenia
observed in clinical trials following exogenous IL-12 administration, IFN-γ nadir occurred at 72 hours; however, in contrast to clinical trials, levels recovered quickly and displayed
positive correlations postburst out to 25 days [67, 68]. The
rapid recovery of secretory capacity following IL-12-NS
administration suggests a lower likelihood of irreversible
overstimulation.
Further, while serum IFN-γ levels in early clinical trials
showed increasingly diminished responses to IL-12 over
time, IL-12-NS-treated mice showed the opposite trend,
which started at the onset of the sill phase and remained
out to 25 days. Moreover, IL-12-NS administration induced
these proinﬂammatory changes while prompting minimal
counterregulatory increases in anti-inﬂammatory IL-10 and
IL-4 cytokine levels [69, 70]. As SIRS is the most feared
complication of recombinant cytokine therapy, IL-12-NSinduced increases in SIRS-associated cytokines could indicate dose-limiting toxicity. Although IL-6 levels increased
to 30-folds of the baseline during the burst phase, they normalized by 72 hours and trended negatively throughout the
sill phase. Similar trends were observed with IL-1β and
CXCL-1, suggesting the potential for immune recovery and
decreased likelihood of progression to a SIRS-like state.
The increase of IFN-γ over time alongside the negative
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Figure 4: Female BALB/c mice were inoculated with 1 mg/kg of Alexa 647-loaded nanospheres dissolved in sterile saline and monitored for
ﬂuorophore distribution (a) systemically over 30 minutes (images presented by time from top [initial tail vein injection], middle [initial i.p.
injection], to bottom [30 minutes postinjection]) via IVIS imaging through i.p. (left) and tail vein (right) injections (∗ indicates IVIS signal
immediately following either injection) and (b) in the bone (left) and lung (right) at four hours postinjection via ﬂuorescent microscopy.

correlate of IL-10 and little to no change in TNF-α as well as
IL-6 suggests that repeated administration of low-dose IL-12
through the vector system IL-12-NS may not produce an
exhaustive cytokinome believed to be associated with treatment failures in previous clinical trials [71]. Given the initial
increase in IFN-γ with a sustained increase over several

weeks in conjunction with a short increase in TNF-α that
normalizes quickly (within 96 hours), and IL-10 levels that
essentially never change, the cytokinome is set perfectly to
achieve sustained immunostimulation without ﬁring the
immunosuppressive response. All of these positive responses
are seen despite utilizing logarithmically lower doses than
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Figure 5: Blood cytokine concentrations of n = 3 mice euthanized at various time points following retroorbital inoculation of 250 million
recombinant mouse IL-12-loaded PLGA nanospheres. Samples normalized to six control mouse cytokinomes and represented as fold
change. For reference, a fold change of one (1) indicates equal cytokine levels in comparison to control, whereas a fold change of two (2)
or one-half (0.5) indicates a respective doubling or halving from physiological levels. Tumor-destroying cytokines, IFN-γ, IL-2, and IL-5,
were sampled at (a) the burst phase—5 minutes (5 m), 6 hours (6 h), and 12 hours (12 h), and (b) the sill phase—24 hours (24 h), 48
hours (48 h), 72 hours (72 h), 96 hours (96 h), 11 days (11 d), 18 days (18 d), and 25 days (25 d), postinoculation. Tumor-promoting, IL10, IL-4, and IL-5 (c, d), and SIRS-associated, IL-1β, IL-6, CXCL-1, and TNF-α (e, f), cytokines are also displayed at the same time
points, graphically separated into burst and sill phases. Statistical diﬀerences were determined using Student’s t test. ∗ p < 0:05, ∗∗ p < 0:01,
and ∗∗∗ p < 0:001.

those delivered during human clinical trials (even when calculated as a ng/kg/day dosing assessment). These data further suggest the importance of the vector system which
safely creates the antitumor, immunostimulatory environment sought by previous researchers.

5. Conclusion
From these results, we conclude that rmIL-12 can be eﬀectively packaged into PLGA nanospheres using the double
emulsion/solvent evaporation (w1/o/w2) technique with
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ultracentrifugation and can achieve a homogenous distribution with a mean particle diameter of 138:1 ± 10:8 nm. Additionally, the nanospheres produced a characteristic elution
proﬁle with early “burst” and late steady-state “sill” phases
with an average steady-state elution of 15 picograms IL-12/
day at a starting concentration of 250 million spheres/mL.
For the in vivo portion of the study, we found that IL-12loaded nanospheres produced a systemic cytokine proﬁle
favoring immunostimulation without long-term elevation
of SIRS-inducing acute phase response cytokines. While a
larger experimental group may need to be tested to further
validate our results, we suggest that IL-12-loaded nanospheres can produce antitumor immune proﬁles without
inducing TCE and SIRS which is deserving of further
investigation.
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